• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Turnstone Biologics Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    11/12/24 4:07:51 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TSBX alert in real time by email
    8-K
    0001764974false00017649742024-11-122024-11-12

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 12, 2024

     

     

    Turnstone Biologics Corp.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-41747

    83-2909368

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    9310 Athena Circle, Suite 300

     

    La Jolla, California

     

    92037

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (347) 897-5988

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock ($0.001 par value)

     

    TSBX

     

    Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On November 12, 2024, Turnstone Biologics Corp. (the “Company”) issued a press release announcing financial results for the three and nine months ended September 30, 2024 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit

    No.

    Description

    99.1

    Press Release dated November 12, 2024, titled "Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights"

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    TURNSTONE BIOLOGICS CORP.

    Date: November 12, 2024

    By:

    /s/ Sammy Farah

    Sammy Farah, M.B.A., Ph.D.

    President and Chief Executive Officer and Director

     


    Get the next $TSBX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TSBX

    DatePrice TargetRatingAnalyst
    2/5/2025$3.75 → $0.40Overweight → Neutral
    Piper Sandler
    11/15/2024Neutral → Underperform
    BofA Securities
    10/14/2024Buy → Neutral
    BofA Securities
    8/16/2023Market Perform
    SVB Securities
    8/15/2023$20.00Overweight
    Piper Sandler
    8/15/2023$18.00Buy
    BofA Securities
    More analyst ratings

    $TSBX
    Leadership Updates

    Live Leadership Updates

    See more
    • Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

      SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies," said Sammy Farah, M.B.A., Ph.D., Turnstone's President and Chief Executive Officer. "The next frontier for TIL therapy is to extend its therapeutic activity

      5/13/24 5:01:26 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics Appoints William Waddill to its Board of Directors

      SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

      4/16/24 9:00:00 AM ET
      $ANNX
      $ARWR
      $PTGX
      $TSBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

      Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 Further strengthened Scientific Advisory Board with appointment of internationally recognized cancer immunotherapy expert, Dr. Jeffrey S. Weber SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported

      3/21/24 5:06:41 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Turnstone Biologics Corp.

      SCHEDULE 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)

      5/12/25 10:43:30 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Turnstone Biologics Corp.

      10-K - Turnstone Biologics Corp. (0001764974) (Filer)

      3/28/25 9:08:30 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Turnstone Biologics Corp. (0001764974) (Filer)

      3/28/25 9:05:31 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights

      SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates. Corporate Updates In January 2025, Turnstone made the determination to discontinue all TIDAL-01 clinical studies and halted further development of the program. As a result, the Company initiated a process to explore a range of potentia

      5/8/25 6:00:49 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer ("SITC") Annual Meeting. Turnstone also presented clinical data at t

      3/28/25 9:03:57 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics Announces Plans to Explore Strategic Alternatives

      SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced that it has completed an assessment of its business and operations, including the status of its program, resources, and capabilities. The Company has made the determination to discontinue all clinical studies evaluating TIDAL-01 and halt further development of the program. As a result, Turnstone's management and its Board of Directors have initiated a process to explore and review strategic alternatives focused on maximizing shareholder value. "Manufacturing for our Selected TIL therapy requires continued investment in process improvements. Due to these capit

      2/4/25 9:00:00 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TSBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Turnstone Biologics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Turnstone Biologics from Overweight to Neutral and set a new price target of $0.40 from $3.75 previously

      2/5/25 8:04:09 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics downgraded by BofA Securities

      BofA Securities downgraded Turnstone Biologics from Neutral to Underperform

      11/15/24 8:23:44 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Turnstone Biologics downgraded by BofA Securities

      BofA Securities downgraded Turnstone Biologics from Buy to Neutral

      10/14/24 7:44:47 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Gould Robert J

      4 - Turnstone Biologics Corp. (0001764974) (Issuer)

      7/2/24 4:45:14 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Gupta Rishi

      4 - Turnstone Biologics Corp. (0001764974) (Issuer)

      7/2/24 4:45:12 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Rajangam Kanya

      4 - Turnstone Biologics Corp. (0001764974) (Issuer)

      7/2/24 4:45:15 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Turnstone Biologics Corp. (Amendment)

      SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)

      5/31/24 4:23:52 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Turnstone Biologics Corp. (Amendment)

      SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)

      4/29/24 8:22:22 AM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Turnstone Biologics Corp.

      SC 13G - Turnstone Biologics Corp. (0001764974) (Subject)

      3/18/24 9:13:28 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSBX
    Financials

    Live finance-specific insights

    See more
    • Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer ("SITC") Annual Meeting. Turnstone also presented clinical data at t

      3/28/25 9:03:57 PM ET
      $TSBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care